微芯生物：自愿披露关于西奥罗尼胶囊治疗转移性胰腺导管腺癌临床试验申请获得受理的公告

Core Viewpoint - Micron Biomedical has received the acceptance notice for the clinical trial application of its self-developed Xioroni capsules for the treatment of metastatic pancreatic ductal adenocarcinoma from the National Medical Products Administration [2] Group 1 - The clinical trial application for Xioroni capsules has been officially accepted, indicating progress in the drug development process [2] - This development highlights the company's commitment to advancing innovative treatments in oncology [2]